Dasatinib

Catalog No.S1021 Synonyms: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 147 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 202 Publications

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Targets
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 MmDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2WzdVczKGh? MWXEUXNQ MX\JR|UxRTBwMECwNFch|ryP M{PzSVE4QTV4MEiw
K562 MljxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTadplWPzJiaB?= NVThflVHTE2VTx?= M3TtcmlEPTB;MD6wNFEh|ryP NXPleoxzOTd7NU[wPFA>
M07e NHjm[mFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUKxW5VnPzJiaB?= NUfFeXlrTE2VTx?= MXPJR|UxRTBwMECxNkDPxE1? M1rqblE4QTV4MEiw
ALL3 NXLY[YRLS3m2b4TvfIlkKEG|c3H5 M{XENVAvOc7:TR?= NVXkZXJUPzJiaB?= Mn3GSG1UVw>? M4DWTmlEPTB;MD6wNFA1KM7:TR?= NH;uNpIyQTh6OUW0NC=>
CML M4W2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzsNlAhdWmw NH\JfmRFVVOR NH;xfJNKSzVyPUCuNFAyKM7:TR?= NHvBRXEyQTJzOUCxOi=>
BA/F3 NIj4WZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPGPGM4OiCq MlTMSG1UVw>? NFzVS4hKSzVyPU[uOVg6KM7:TR?= MoTxNlMxQDh4NES=
BA/F3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXe3NkBp MV\EUXNQ NUP5N4FGUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBOOzVzVDDteZRidnRid3n0bEBKSzVyIH;mJFAvODByOEROwG0> MWOyN|A5QDZ2NB?=
BA/F3 NVHLR3o2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2raSlczKGh? MkLlSG1UVw>? MVnJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzD3bYxlKHS7cHWgRoNzNUGkbDD3bZRpKEmFNUCgc4YhOC5yMES1{txO MXKyN|A5QDZ2NB?=
BA/F3 NEXlRpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1j6elczKGh? NWHCWoZITE2VTx?= NUPXeohbUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBVOzF3STDteZRidnRid3n0bEBKSzVyIH;mJFEvPzF2zszN M1zwSFI{ODh6NkS0
BA/F3 NIP6N2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlH0O|IhcA>? MYXEUXNQ MVzJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBHPDh4UzDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECwPe69VQ>? M1L1OVI{OzBzN{Cz
BA/F3 NGTXO5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVv2W3NPPzJiaB?= NXHmfYk6TE2VTx?= NXPhSWd4UW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRUK1OWshdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOzMQvF2= MXuyN|MxOTdyMx?=
BA/F3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3xO|IhcA>? MnPESG1UVw>? NFz3SI9KdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCJMkWwSUBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA2Oc7:TR?= Mm[3NlM{ODF5MEO=
BA/F3 NITnfodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXTO|IhcA>? NEj6T4ZFVVOR NUn4OnZ{UW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiUUK1NmghdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxQM7:TR?= NGDi[pUzOzNyMUewNy=>
BA/F3 NYPOdWlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWK3NkBp M1\3d2ROW09? M2jHZ2lv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV|NUnWJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFE{|ryP NEPkcZMzOzNyMUewNy=>
BA/F3 NUf5ZnZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXO3NkBp MojySG1UVw>? MWrJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKFUj3BRmwh[XO|ZYPz[YQh[XNiZ4Lve5RpKEmwaHnibZRqd25id3n0bEBKSzVyIH;mJFAvODBzOd88US=> NGDXTFkzOzNyMUewNy=>
BA/F3 NH3CfHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnyO|IhcA>? M1TzVGROW09? NXTDW2NEUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiWUK1N2ghdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOjQQvF2= NXS1Nm1bOjN|MEG3NFM>
BA/F3 NWD4RW44T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHQe3V{PzJiaB?= NFvqbYlFVVOR M3vkW2lv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFR|MUXJJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMz62{txO MnjTNlM{ODF5MEO=
BA/F3 MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVy3Xpk3PzJiaB?= MofPSG1UVw>? MmPkTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghUW6qaXLpeIlwdiC5aYToJGlEPTBib3[gNk42|ryP NWq1XZl6OjN|MEG3NFM>
T cell NVv0PHdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYe3NkBp MWTEUXNQ MoTiTY5pcWKrdIOgZY51cSCFREOtJIFv\CCjboTpJGNFOjhvaX7keYNm\CCWIHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5yMEROwG0> MWSxO|E2PDVzMh?=
WiDr NEHkeZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvvT3R6PzJiaB?= Mkm4SG1UVw>? M2HVe2lEPTB;MD6wOVIh|ryP NGG1RmcyPTZzNUWxNi=>
PC3 M1\TdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PZR|czKGh? MY\EUXNQ NH7Yc3hKSzVyPUCuNFA6PCEQvF2= M2HHSVE2PjF3NUGy
MDA-MB-231 MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIS5VnA4OiCq NGXHfWdFVVOR MkXMTWM2OD1yLkCxNkDPxE1? MmHONVU3OTV3MUK=
Hs578T M3e2V2N6fG:2b4jpZ{BCe3OjeR?= MUC3NkBp MWHEUXNQ NXLJTZdKT0l3ME2wMlA{KM7:TR?= M1PPdVI1ODF3M{K3
HMEC MmPZR5l1d3SxeHnjJGF{e2G7 NF3ZXXE4OiCq NVq3T3VvTE2VTx?= NG\2WphIUTVyPUGuPEDPxE1? NWLGfmhJOjRyMUWzNlc>
DU145 MXjDfZRwfG:6aXOgRZN{[Xl? M4nDdFczKGh? NGH2OIVFVVOR MVrHTVUxRTBwMU[g{txO NFXOTG0zPDBzNUOyOy=>
U251 MX3DfZRwfG:6aXOgRZN{[Xl? M2q4WlczKGh? NIXWSo5FVVOR M1rzZWdKPTB;Mj64NUDPxE1? NUjqVJNHOjRyMUWzNlc>
NCI60 NYfo[nV[S3m2b4TvfIlkKEG|c3H5 MoDkO|IhcA>? NFfHXWFFVVOR MXjHTVUxRTVwNzFOwG0> MljSNlQxOTV|Mke=
MALME-3M MnrnR5l1d3SxeHnjJGF{e2G7 NEnuN4o4OiCq M{e4dWROW09? MmS5S2k2OD14Lk[xJO69VQ>? NWTVTlhMOjRyMUWzNlc>
KM12 MUPDfZRwfG:6aXOgRZN{[Xl? NWnXZmxKPzJiaB?= NUHWZmR1TE2VTx?= MU\HTVUxRTdwNESg{txO MmDoNlQxOTV|Mke=
SW620 NG\mfoZEgXSxdH;4bYMhSXO|YYm= M3nuW|czKGh? M3TyNGROW09? NXXLeo9GT0l3ME24MlQ{KM7:TR?= M{PpWVI1ODF3M{K3
RXF 393NL M1HqfGN6fG:2b4jpZ{BCe3OjeR?= NWHVXldnPCCmYYnz NXTQUlhqTE2VTx?= NF64dlBKSzVyPUCuNFIyPyEQvF2= MVuyN|I2OzB5NB?=
LXFA 983L NWDKZplZS3m2b4TvfIlkKEG|c3H5 NIe1OpU1KGSjeYO= MonkSG1UVw>? NIPlPZpKSzVyPUCuNFU3PSEQvF2= M{DicFI{OjV|MEe0
PRXF DU145 MlvyR5l1d3SxeHnjJGF{e2G7 MXK0JIRigXN? NYCyblZZTE2VTx?= MVvJR|UxRTBwME[yN{DPxE1? MknyNlMzPTNyN{S=
PAXF 1657L NUXMWG9iS3m2b4TvfIlkKEG|c3H5 MU[0JIRigXN? NWPpPJBuTE2VTx?= NVPRfpl5UUN3ME2wMlEzOSEQvF2= NXjaVGhHOjN{NUOwO|Q>
CXF 1103L M2H2UWN6fG:2b4jpZ{BCe3OjeR?= NWrvdnlCPCCmYYnz MljMSG1UVw>? NUnXdGd6UUN3ME20MlM3KM7:TR?= MmLwNlMzPTNyN{S=
GXF251L MUDDfZRwfG:6aXOgRZN{[Xl? MWm0JIRigXN? M1LrV2ROW09? MWTJR|UxRTJwMkWg{txO MVWyN|I2OzB5NB?=
NCI-H23 NE\UfnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoH6O|IhcA>? M{j0S2ROW09? NYnVdW1nUUN3ME2yMlI4KM7:TR?= MlP6NlM2OjFyMkC=
HCT116 NX3wPZZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPPO|IhcA>? M2LUWmROW09? NXzIWFNZUUN3ME2yMlMh|ryP MnTINlM2OjFyMkC=
MCF7 NIWwWYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvSO|IhcA>? NV3iW3FCTE2VTx?= Mmr5TWM2OD1{LkW3JO69VQ>? M1\VR|I{PTJzMEKw
NCI-H460 Mle4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLudHJGPzJiaB?= NUKzZm5QTE2VTx?= MXzJR|UxRThwOUmg{txO MlvJNlM2OjFyMkC=
DLD1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\3[FczKGh? NF34XlZFVVOR MVjJR|UxRTRwNjFOwG0> M{nLR|I{PTZ5OU[w
NCI-H661 MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHFO|IhcA>? NUL1PZR4TE2VTx?= NUPsbGhqUUN3ME23Mlgh|ryP MVSyN|U3Pzl4MB?=
A549 M37WfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[3NkBp MYnEUXNQ MlvrTWM2OD16LkKg{txO MknJNlM2Pjd7NkC=
U937 Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIS2VHY4OiCq MmnySG1UVw>? NG\zXnJKSzVyPUGyMlIh|ryP NH[0VZczOzV4N{m2NC=>
HEK293 NFnBXWlHfW6ldHnvckBCe3OjeR?= M3;WflExyqEQvF2= M1HrdGROW09? MojkTY5lfWOnczDibY5lcW6pIHHm[olvcXS7IITvJIh2dWGwIH\1cIwudGWwZ4ToJGhqey22YXfn[YQhVXm2MTDrbY5ie2ViZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyC5aYToJGlEPTBib3[gNE4xPjQQvF2= NHf5RoozOjd5ME[xNC=>
HUVEC NF\KdZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV:wMlE2yqEQvF2= Mn7pO|IhcA>? NV\pNpR4TE2VTx?= MorPTY5lfWOnczDhcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCrbjDIWXZGSyClbz3jeYx1fXKnZDD3bZRpKH[jc3P1cIFzKHOvb3;0bEBufXOlbHWgZ4VtdHNiYYPz[ZN{\WRiYYOgTY5pcWKrdHnvckBw\iClZXzsJIdzd3e2aDDheEAxNjF3IIXN NH;vNZczOjh3M{m5Ny=>
HUVEC MYPGeY5kfGmxbjDBd5NigQ>? NEjDfoMyPcLizszN NF7Rd2U4OiCq M1zYU2ROW09? MX7JcoR2[2W|IHHueIlidmerb3flcolkKGGldHn2bZR6KGmwIFjVWmVEKGOxLXP1cJR2emWmIIfpeIghfmG|Y4XsZZIhe22xb4ToJI12e2OuZTDj[YxteyCjc4Pld5Nm\CCjczDJcohq[mm2aX;uJI9nKG6ndIfvdosh\m:{bXH0bY9vKGG2IEGuPEB1dyBzNTD1US=> NYfFXZBVOjJ6NUO5PVM>
Plasmodium falciparum M3;ocmZ2dmO2aX;uJGF{e2G7 NFfubnIyOMLizszN NXfnd3dNOTVibXnu NXTvNFMzTE2VTx?= NIiweY5KdmirYnn0d{BRdGG|bX;kbZVuKG[jbHPpdIFzfW1icILvcIln\XKjdHnvckBjgSCrbnjpZol1cW6pIITo[UBHfW6ldHnvckBw\iCSZlPEVGsyKHC{b4TlbY4hf2m2aDDJR|UxKG:oIEGuNVfPxE1? NV2zUoFTOjR3NUCzN|A>
PC3 M1nH[GZ2dmO2aX;uJGF{e2G7 Mn3WNE4yKM7:TR?= M4PZRlUhcA>? NF[4cFhFVVOR NX7MZ254UW6qaXLpeJMhcHWvYX6gVGM{KGOnbHygZYRp\XOrb36gZZQhOTByIH7N M1nISlE6PDZ{OUe1
DU145 MXHGeY5kfGmxbjDBd5NigQ>? NHixVFQxNjFizszN NVLkT2RvPSCq NF;YNIRFVVOR NWDNU2ppUW6qaXLpeJMhcHWvYX6gSHUyPDViY3XscEBi\Ginc3nvckBifCBzMECgcm0> NEHz[nAyQTR4Mkm3OS=>
PC3 M{jBXGtqdmG|ZTDBd5NigQ>? NF[5[40xNjFizszN NV7lPZBIPSCq M2fVPGROW09? Mln2TY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCSQ{OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJHNz[yC\NEG2JIxmfmWuIHH0JFExOCCwTR?= M2XDXFE6PDZ{OUe1
DU145 MWTLbY5ie2ViQYPzZZk> M{XrZlAvOSEQvF2= MlvsOUBp MlLaSG1UVw>? M2LvO2lvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKFO{YzDZOFE3KGyndnXsJIF1KDFyMDDuUS=> NGHuNWYyQTR4Mkm3OS=>
PC3 M2fjWWtqdmG|ZTDBd5NigQ>? M2W5[|AvOSEQvF2= NHLTZXQ2KGh? MnfhSG1UVw>? M13Fc2lvcGmkaYTzJINUemNiaX6gbJVu[W5iUFOzJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBHSUtiWUW3Ok9[PTd5IHzleoVtKGG2IEGwNEBvVQ>? NHjw[2syQTR4Mkm3OS=>
DU145 MVjLbY5ie2ViQYPzZZk> M{e0[|AvOSEQvF2= NG\nRVE2KGh? MXnEUXNQ MXfJcohq[mm2czDjV5JkKGmwIHj1cYFvKESXMUS1JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBHSUtiWUW3Ok9[PTd5IHzleoVtKGG2IEGwNEBvVQ>? NFroXIIyQTR4Mkm3OS=>
Huh7 NUTobJFDSW62aY\pdoFtKEG|c3H5 Mn7mNk42KM7:TR?= M{XMVFQh\GG7cx?= MXjEUXNQ NEfRRoFKdmirYnn0d{B3cXKjbDDzdJJm[WRiaX6gSIVv\3WnII\pdpV{NWmwZnXjeIVlKGi3bXHuJGh2cDdiY3XscJMh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJI9nKH[rcnHsJIVvfmWub4DlJJBzd3SnaX6ge4l1cGmwIIDldolvfWOuZXHyJJJm\2mxbjDheEAzNjVidV2= NF7EVokyPzN4ME[3Oi=>
C6/36 M{PHUGFvfGm4aYLhcEBCe3OjeR?= MV[yMlUh|ryP MkDaOEBl[Xm| NUfiTG5lTE2VTx?= NYLyPVlyUW6qaXLpeJMhfmm{YXygd5Bz\WGmIHnuJGRmdme3ZTD2bZJ2ey2rbn\lZ5Rm\CCjc3nhckB1cWencjDtc5NyfWm2bzDDOk8{PiClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TR?= M{LrZ|E4OzZyNke2
U937 MYHGeY5kfGmxbjDBd5NigQ>? Mlf0NUDPxE1? NXPjRVBUOSCq Mn;wSG1UVw>? NEj1NFdT\WS3Y3XzJIJie2GuIGTOSoFteGijIILlcIVie2ViaX6gbJVu[W5iVUmzO{Bk\Wyucx?= NEPEdoEyPzZ6NEC5PS=>
U937 MVnGeY5kfGmxbjDBd5NigQ>? NIexeVgyKM7:TR?= NVT4OmN6OSCq NEDXV3hFVVOR MonUVoVlfWOnczDMVHMucW6mdXPl[EBVVk[jbIDoZUBz\WynYYPlJIlvKGi3bXHuJHU6OzdiY3XscJM> MVmxO|Y5PDB7OR?=
murine mast cell Mnj5SpVv[3Srb36gRZN{[Xl? NV3NV2M6OSEQvF2= M{nCflI1KGh? MlPLSG1UVw>? M33qN2lvcGmkaYTzJIFvfGmpZX6tbY5lfWOnZDDJUFYhe2WlcnX0bY9vKGmwIFnnSUBxemmvZXSgcY92e2VibXHzeEBk\WyuczDheEAyKHWP NXrwRmJJOTd4OESwPVk>
BV-173 MoPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlr5TWM2OD1yLkCwNFAxODFyOTFOwG0> NYX5b3JPW0GQR1XS
K-562 NX7yenBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUK4fYg6UUN3ME2wMlAxODByMEK2OkDPxE1? M4i4[XNCVkeHUh?=
BL-70 M3nPXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUmze3E5UUN3ME2wMlAxODByMEiyNkDPxE1? NVTHNnRVW0GQR1XS
EM-2 M17LTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwMECwNFAyODhizszN MoHNV2FPT0WU
LAMA-84 Ml72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jzcmlEPTB;MD6wNFAxODN{MTFOwG0> NYjpe2YzW0GQR1XS
MEG-01 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX35S4p7UUN3ME2wMlAxODByOUig{txO MV\TRW5ITVJ?
EoL-1-cell NWXVZ3lQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwMECwNFE{OSEQvF2= MV;TRW5ITVJ?
CTV-1 NV;TXYo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmizTWM2OD1yLkCwNFA1ODRizszN M1X6PXNCVkeHUh?=
TE-15 NUnOWWZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfZTWM2OD1yLkCwOVg6KM7:TR?= NVniWGxIW0GQR1XS
NOS-1 MofpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrWO5dKSzVyPUCuNFA3OTNizszN Mn3hV2FPT0WU
D-336MG MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nq[mlEPTB;MD6wNFY{KM7:TR?= MUPTRW5ITVJ?
LB1047-RCC NXf4U5FMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HBdmlEPTB;MD6wNFk5QSEQvF2= MojhV2FPT0WU
LB996-RCC M4PnR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfsTVVKSzVyPUCuNFA6QTFizszN NHLae2NUSU6JRWK=
SW982 NH2xcHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLRTWM2OD1yLkCxNVE2KM7:TR?= NVjnZVJsW0GQR1XS
TK10 M{L4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnre2hKSzVyPUCuNFEyPzRizszN NGDDWpJUSU6JRWK=
A704 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7oTWM2OD1yLkCxOFkyKM7:TR?= NWDYcYlTW0GQR1XS
TE-8 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHORmRKSzVyPUCuNFE2PzZizszN NFHSeZZUSU6JRWK=
DOHH-2 NHn0d3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTFV|NKSzVyPUCuNFE4OTlizszN NUm4dohIW0GQR1XS
HOP-62 M3zqS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3LSIRXUUN3ME2wMlAyQDN2IN88US=> NILv[mdUSU6JRWK=
TE-12 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{H2OGlEPTB;MD6wNVg3OSEQvF2= NX7DZo1uW0GQR1XS
KGN M36xTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLFdlF{UUN3ME2wMlAyQTR{IN88US=> MVvTRW5ITVJ?
NCI-H1648 NIDQOndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrjZ5VUUUN3ME2wMlAzODFzIN88US=> NEmxdHZUSU6JRWK=
OS-RC-2 NWLFSWhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\VTWlEPTB;MD6wNlA{KM7:TR?= NGjE[HNUSU6JRWK=
GB-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVn3VnRTUUN3ME2wMlAzOTV5IN88US=> NELacVRUSU6JRWK=
RXF393 M1TpXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLTS4NKSzVyPUCuNFI{PTdizszN NWTmfFNKW0GQR1XS
LC-2-ad M3HWfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7BTYVMUUN3ME2wMlAzPTh4IN88US=> NI[xV2RUSU6JRWK=
KS-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjxOYNKSzVyPUCuNFI4OyEQvF2= MmnJV2FPT0WU
ETK-1 M2H3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwMEK4N|Ih|ryP MUTTRW5ITVJ?
SW954 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XvXGlEPTB;MD6wNlkzPyEQvF2= MoHLV2FPT0WU
Becker Ml:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;ORWlEPTB;MD6wN|AxOyEQvF2= NWiyOFFpW0GQR1XS
MZ1-PC NFvEOXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLwfoRKSzVyPUCuNFMyOTlizszN M3XjUHNCVkeHUh?=
ES6 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGD2Xm9KSzVyPUCuNFMyQTNizszN MUnTRW5ITVJ?
KURAMOCHI NX3iN2tbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nZbmlEPTB;MD6wN|Q5PyEQvF2= NELnVoJUSU6JRWK=
CGTH-W-1 NYLtTZozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XlUGlEPTB;MD6wN|U1QCEQvF2= MmC5V2FPT0WU
VA-ES-BJ NGTWV4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwMEO5NFIh|ryP NIXpUHpUSU6JRWK=
LXF-289 NIK1VGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHzXVNKSzVyPUCuNFM6PTZizszN NFPM[HJUSU6JRWK=
MPP-89 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17TdGlEPTB;MD6wOFA1QSEQvF2= M1HQU3NCVkeHUh?=
SW872 NUHmPJJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnKe5BKSzVyPUCuNFQyPjFizszN M4nsU3NCVkeHUh?=
SNB75 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fvcWlEPTB;MD6wOFQ{PSEQvF2= M4n0R3NCVkeHUh?=
PSN1 NFzwO2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPubmNKSzVyPUCuNFQ1PzRizszN MV;TRW5ITVJ?
LB831-BLC M3jkTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYK2OYtTUUN3ME2wMlA1PjB7IN88US=> NU\teZR1W0GQR1XS
MFH-ino MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkWzTWM2OD1yLkC0O|I1KM7:TR?= NX3ue5ptW0GQR1XS
TGBC24TKB MlLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwMES3OlEh|ryP MXjTRW5ITVJ?
A388 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUOxW4RnUUN3ME2wMlA2ODl3IN88US=> MXjTRW5ITVJ?
BB30-HNC NVLocYtJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETiZYdKSzVyPUCuNFU1OzdizszN MkXhV2FPT0WU
GI-ME-N NFPiVIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjJTWM2OD1yLkC2NVE5KM7:TR?= MXXTRW5ITVJ?
TGBC1TKB MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHmTWM2OD1yLkC2NVY1KM7:TR?= MoTyV2FPT0WU
TE-10 M1PERmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvETWM2OD1yLkC2N|U4KM7:TR?= MYHTRW5ITVJ?
A498 M3ziXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTBwMEeyPFQh|ryP MYfTRW5ITVJ?
TE-11 MkTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfWUW9KSzVyPUCuNFc5PThizszN M4K2fHNCVkeHUh?=
BB65-RCC MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEn0bpFKSzVyPUCuNFgzOjdizszN MofRV2FPT0WU
C2BBe1 Mlr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPBO2xDUUN3ME2wMlA5OzB6IN88US=> NV3Wd5dtW0GQR1XS
NCI-H747 NXPvW5ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUH2[odVUUN3ME2wMlA5OzZ{IN88US=> NF\ZUYFUSU6JRWK=
IST-MES1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPvfZBLUUN3ME2wMlA5PTV{IN88US=> MmTZV2FPT0WU
KALS-1 M3LOTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrqRnd1UUN3ME2wMlA6PDlizszN M4W1XXNCVkeHUh?=
GCIY NGXUVZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwMEm2OVYh|ryP MkjlV2FPT0WU
RL95-2 NHzRb5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXITWM2OD1yLkGwN|gh|ryP Mn3GV2FPT0WU
TE-1 NXrQOHl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XQcmlEPTB;MD6xNFU1KM7:TR?= MUjTRW5ITVJ?
NCI-H1355 MoHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;odGlEPTB;MD6xNVAzQCEQvF2= Ml3rV2FPT0WU
SW962 NWm4WGYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rr[GlEPTB;MD6xNVI6OiEQvF2= MYLTRW5ITVJ?
KLE MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17sdmlEPTB;MD6xNVMyPyEQvF2= NGK0b5lUSU6JRWK=
MC116 M2DIR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwMUG0NUDPxE1? NYTaOnU4W0GQR1XS
NMC-G1 M{XvOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnflTWM2OD1yLkGxOlA3KM7:TR?= MV3TRW5ITVJ?
KU812 MnX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnr[WVKSzVyPUCuNVE5QDNizszN MXHTRW5ITVJ?
COLO-829 Mkj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInYe5RKSzVyPUCuNVIzOTNizszN MXXTRW5ITVJ?
NTERA-S-cl-D1 Mnn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFf2Ro9KSzVyPUCuNVIzQDNizszN NV\vTmRGW0GQR1XS
IST-MEL1 NYG1c4kxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mne0TWM2OD1yLkGzOFUh|ryP NWfEeZpZW0GQR1XS
MLMA M1Tnbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\3RWlEPTB;MD6xOFA{OiEQvF2= NEDWTWVUSU6JRWK=
LS-123 NFXMWldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnWwTWM2OD1yLkG0NFY1KM7:TR?= NH3lblZUSU6JRWK=
LB2518-MEL M2fVcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwMUSxOlIh|ryP NELUenlUSU6JRWK=
NB69 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVH6PIVyUUN3ME2wMlE1PDN4IN88US=> M4i0XHNCVkeHUh?=
8-MG-BA NWfZNGNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HK[2lEPTB;MD6xOVQ2QCEQvF2= NWj5OnpYW0GQR1XS
K5 MnOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\YTWM2OD1yLkG2OFg6KM7:TR?= M2S4eHNCVkeHUh?=
KINGS-1 Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEn4dmNKSzVyPUCuNVY3PjZizszN M1\Tb3NCVkeHUh?=
SF268 MleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1mwN2lEPTB;MD6xO|QxPCEQvF2= MlyxV2FPT0WU
PF-382 MoTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwMUe2O|gh|ryP NGXqe4ZUSU6JRWK=
SH-4 M1HBZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnIc4pKSzVyPUCuNVg1OTNizszN NXrt[3dSW0GQR1XS
NALM-6 NHPaboRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DCZWlEPTB;MD6xPVI6PSEQvF2= NIrCN|hUSU6JRWK=
CP66-MEL M1\VWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwMUm1N|Eh|ryP NXLNRWRsW0GQR1XS
697 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrm[2hKSzVyPUCuNVk6QDdizszN MnPZV2FPT0WU
CP67-MEL NET2N2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PDVWlEPTB;MD6yNFQ5QCEQvF2= NX[1OHFOW0GQR1XS
DSH1 NHjQSWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfWTWM2OD1yLkK0NFAyKM7:TR?= M4rkdXNCVkeHUh?=
HCE-4 MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;iS4pKSzVyPUCuNlY1OzlizszN NXzkNFJLW0GQR1XS
MZ2-MEL MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XWRWlEPTB;MD6yPFU{PyEQvF2= MV7TRW5ITVJ?
BL-41 NG\1OXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrwTWM2OD1yLkK5NVI{KM7:TR?= NHTYXmNUSU6JRWK=
HUTU-80 MmPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;tTWM2OD1yLkOxOFIh|ryP MV\TRW5ITVJ?
LOXIMVI NV;aXWI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwM{G1NFMh|ryP Mmm0V2FPT0WU
no-10 M1WxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTxfWtIUUN3ME2wMlMyQTNzIN88US=> NVHseVB5W0GQR1XS
KARPAS-422 NFLGSJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTaTWM2OD1yLkOzPVk4KM7:TR?= MmHDV2FPT0WU
SW684 Mn3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFGyRnlKSzVyPUCuN|Q6QCEQvF2= NXPhc2l{W0GQR1XS
SF126 MmnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPiTWJKSzVyPUCuN|U1OSEQvF2= NWLHT5hsW0GQR1XS
D-263MG MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTBwM{[yNlQh|ryP MmHGV2FPT0WU
OVCAR-4 NGTx[49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTBwM{e0N|Mh|ryP MoO4V2FPT0WU
BB49-HNC MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HsWWlEPTB;MD6zPFU6QSEQvF2= MX\TRW5ITVJ?
ONS-76 NFrRdW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITTPVhKSzVyPUCuOFI6PTFizszN MVLTRW5ITVJ?
MZ7-mel MkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvvd2Z4UUN3ME2wMlQ4QTFzIN88US=> NV\He3lsW0GQR1XS
RCC10RGB MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXIflE6UUN3ME2wMlQ6OTFizszN M2j1d3NCVkeHUh?=
BOKU MofMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPGTWM2OD1yLkS5NVM{KM7:TR?= M2nDWnNCVkeHUh?=
no-11 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwNUCyNlgh|ryP M4r4TnNCVkeHUh?=
IST-SL2 M{[xN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwNUCzNFIh|ryP M2O1WnNCVkeHUh?=
RKO NUPRcFZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwNUK5OlYh|ryP MVLTRW5ITVJ?
HT-144 MkjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVi0TGoxUUN3ME2wMlU{PjB7IN88US=> MnXpV2FPT0WU
NCI-H446 NYrHPYtoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{H3UGlEPTB;MD62Nlc3KM7:TR?= Ml;lV2FPT0WU
QIMR-WIL MnPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4W4cmlEPTB;MD63NFYzQSEQvF2= NY\2THY6W0GQR1XS
MHH-PREB-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{mxVWlEPTB;MD63OFQ3QSEQvF2= NGjuO5FUSU6JRWK=
EW-16 NYDTbYpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonFTWM2OD1yLke2NVc5KM7:TR?= NED6[XBUSU6JRWK=
EW-24 NFvESIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlH3TWM2OD1yLke4NVY2KM7:TR?= NITqb3BUSU6JRWK=
LB373-MEL-D NX\RNZNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTBwOEK1NFgh|ryP NFzpeIJUSU6JRWK=
TE-9 NX7VbWpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\rTWM2OD1yLki3OVMzKM7:TR?= MV\TRW5ITVJ?
A3-KAW MkTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDLTWM2OD1yLkm4OFUzKM7:TR?= NXfC[3Z{W0GQR1XS
A101D NXfYe2J4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{i5TmlEPTB;MT6wN|A1OyEQvF2= M3rSZnNCVkeHUh?=
OCUB-M MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHwTWM2OD1zLkC0OFEzKM7:TR?= MVLTRW5ITVJ?
ES4 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{i3cmlEPTB;MT6wOVE1PSEQvF2= M4XJWXNCVkeHUh?=
TE-6 NUX2WW9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjHbWhZUUN3ME2xMlIyOjJ4IN88US=> MY\TRW5ITVJ?
D-502MG NWTEeZptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfQNFhKSzVyPUGuNlM{PzZizszN NWTuS2F1W0GQR1XS
KNS-42 NUHVcHY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfEZ2lvUUN3ME2xMlI1PDF{IN88US=> NILrZ|hUSU6JRWK=
SNU-C2B NXS1WWhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmL2TWM2OD1zLkOwOVg6KM7:TR?= MlzlV2FPT0WU
NCI-H1838 NUXHTHJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHQdnFKSzVyPUGuN|A4OzNizszN MkDPV2FPT0WU
NKM-1 M1LnXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHzTWM2OD1zLkOwPFU6KM7:TR?= NHPFdWhUSU6JRWK=
GI-1 M3n6O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGL0cmxKSzVyPUGuN|YzOiEQvF2= NWrYPZNoW0GQR1XS
NB5 M{LvNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTFwM{m4Nlch|ryP M4HJSHNCVkeHUh?=
CAS-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTFwNEC5PVIh|ryP NGG1TZFUSU6JRWK=
HCE-T M{TMXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTGfmRKSzVyPUGuOVY4OTRizszN NFKyXFRUSU6JRWK=
SBC-1 NFL2[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmCxTWM2OD1zLkW3PVg1KM7:TR?= M1O5eHNCVkeHUh?=
JiyoyeP-2003 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTFwN{O0OlYh|ryP NX7JW|lzW0GQR1XS
TE-5 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\VTWM2OD1zLke5NVM6KM7:TR?= M3HScXNCVkeHUh?=
CAN M1LxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXPNGFKSzVyPUGuPFIzPTJizszN MmP4V2FPT0WU
SK-UT-1 M37EO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTJwMU[2PVMh|ryP Mlz3V2FPT0WU
JVM-2 NFrHNJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\PTWM2OD1{LkO2Nlg1KM7:TR?= NHTw[YZUSU6JRWK=
LB771-HNC NED6WlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jSWWlEPTB;Mj61O|U2OSEQvF2= MnfRV2FPT0WU
NCCIT MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fweGlEPTB;Mj64OlYyPiEQvF2= Mk\JV2FPT0WU
NCI-H2126 M3vKVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nzVWlEPTB;Mj64O|U2OiEQvF2= NEHRT2pUSU6JRWK=
Calu-6 M{L1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTNwMEW3OFEh|ryP NGfhclJUSU6JRWK=
SK-LMS-1 NILJUFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTNwMUG4PFYh|ryP MXPTRW5ITVJ?
ARH-77 M1:4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTNwNE[5NVUh|ryP MVLTRW5ITVJ?
NB17 NV;NOYlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\JWY1KSzVyPUOuOlM5PDdizszN MX3TRW5ITVJ?
A253 NVvoTYRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTNwN{OyOFYh|ryP NFHzeG5USU6JRWK=
OPM-2 MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHZRlVKSzVyPUSuNlc3QDVizszN NXrQcXpXW0GQR1XS
MV-4-11 M1TQUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTSbmFVUUN3ME20MlM3PDV2IN88US=> MnHjV2FPT0WU
SR MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4H5fmlEPTB;ND60PVk2PCEQvF2= M1:1bXNCVkeHUh?=
KG-1 NY\wWZhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;UTWM2OD12Lk[wPFQ2KM7:TR?= NFfVOnZUSU6JRWK=
OCI-AML2 Mmr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTVwOE[xOVQh|ryP NXzSeYp[W0GQR1XS
D-247MG MnfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEm1dYJKSzVyPU[uNVI2OTlizszN MWLTRW5ITVJ?
DJM-1 MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\YPVloUUN3ME22MlQ5PTV6IN88US=> NIH4UGhUSU6JRWK=
RPMI-6666 NG\CcYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTdwMkewOlch|ryP NIjVNHpUSU6JRWK=
KARPAS-45 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTdwNUG2O|Eh|ryP MUTTRW5ITVJ?
LP-1 NHjV[mhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXnTWZzUUN3ME23MlU1Pzh{IN88US=> MmnXV2FPT0WU
RS4-11 M{TRN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jrOmlEPTB;Nz62OVc5PyEQvF2= Mme5V2FPT0WU
DU-4475 M{PHTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjuTWM2OD16LkKxOlUzKM7:TR?= M1v0dnNCVkeHUh?=
MONO-MAC-6 NEi2WW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPmXldFUUN3ME24MlI4ODZ4IN88US=> NFHuO5lUSU6JRWK=
NCI-SNU-16 M4\LUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3uwPGlEPTB;OD61OlEzQCEQvF2= MUPTRW5ITVJ?
SJSA-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELoNm9KSzVyPUiuO|I5ODVizszN NVzEXFlyW0GQR1XS
MMAC-SF MoHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRThwN{mzNFch|ryP MojzV2FPT0WU
SK-NEP-1 NXnIZZMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVr0U|lJUUN3ME24Mlg6OTV3IN88US=> M1fpbXNCVkeHUh?=
J-RT3-T3-5 NHLKcWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TWOWlEPTB;OD65OlUzQSEQvF2= MmG4V2FPT0WU
SKM-1 M4\3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHvVlZmUUN3ME25MlAyPzN2IN88US=> Mln3V2FPT0WU
LB2241-RCC MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TES2lEPTB;OT6wNlAyOiEQvF2= MWrTRW5ITVJ?
SIG-M5 M{C1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvPV2hKSzVyPUmuNFI1QTNizszN NFnoenJUSU6JRWK=
EVSA-T M3\ydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2O2dGlEPTB;OT6yO|c6OyEQvF2= NUXReGFNW0GQR1XS
GT3TKB NU\iVm9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrMWHB7UUN3ME25MlM2PTR4IN88US=> M{SwN3NCVkeHUh?=
NB6 M1v0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXv[ZB7UUN3ME25MlkzOjV7IN88US=> MWLTRW5ITVJ?
EHEB NWDaU2xpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DjWmlEPTB;MUCuNFY2PiEQvF2= NUSz[o5lW0GQR1XS
HEL M4HzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoezTWM2OD1zMD60O|c3KM7:TR?= MnPqV2FPT0WU
ALL-PO MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXm[XFKSzVyPUGwMlc6OzhizszN NGnCNVRUSU6JRWK=
TGW MlnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3PTWM2OD1zMT6yPFI5KM7:TR?= M13iO3NCVkeHUh?=
BC-3 NIDMbHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfkTIRKSzVyPUGyMlEyOzhizszN MVvTRW5ITVJ?
IA-LM MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HhVGlEPTB;MUKuOFQ1PSEQvF2= NGTycJpUSU6JRWK=
UACC-257 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;zNmlEPTB;MUKuPVE6QCEQvF2= MWLTRW5ITVJ?
KP-N-YS MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUn1V|Q3UUN3ME2xNk46Ojh|IN88US=> NHT6UGNUSU6JRWK=
Raji MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\FTWM2OD1zMz63OFk4KM7:TR?= NHjHW4hUSU6JRWK=
SF539 NF\5VZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTF|Lki1OVch|ryP MVfTRW5ITVJ?
DMS-153 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTF2LkCwNlgh|ryP NV7FTohFW0GQR1XS
L-540 MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEOxOFZKSzVyPUG1MlA3PzJizszN M3H2[3NCVkeHUh?=
MN-60 NES1WnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTF3LkG5O|kh|ryP NWD0WpdEW0GQR1XS
RPMI-8866 NVnSWIhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnL3TWM2OD1zNz60OFU1KM7:TR?= NWjGS3hGW0GQR1XS
NCI-H510A MonlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHGTJlJUUN3ME2xPU4{QTd|IN88US=> NXv2UZFKW0GQR1XS
NB13 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3vTWM2OD1zOT60PFc4KM7:TR?= NGjWcGhUSU6JRWK=
HAL-01 MmfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PZcWlEPTB;MUmuO|U1OyEQvF2= MojHV2FPT0WU
NCI-H720 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnI[pdKSzVyPUKwMlI4OzNizszN MmPEV2FPT0WU
REH MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjnPGdPUUN3ME2yNE43OzV5IN88US=> NF[5e|NUSU6JRWK=
KNS-81-FD Mme2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrEbI9ZUUN3ME2yN{4yPDZizszN NH;ie4tUSU6JRWK=
HC-1 MnvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTJ2LkW1OVEh|ryP NYHOZVFQW0GQR1XS
NCI-H2141 MljTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zMTGlEPTB;MkSuO|c2PCEQvF2= NGTYfnZUSU6JRWK=
MOLT-4 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\xbnBwUUN3ME2yOk43PzV|IN88US=> M3jxUXNCVkeHUh?=
OMC-1 Ml64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPXTWM2OD1{Nz6xOFIzKM7:TR?= NF7NO3VUSU6JRWK=
LC-1F MkTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTJ5LkOyOFUh|ryP MVnTRW5ITVJ?
NCI-H1304 MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnCTWM2OD1{OD6xOlI5KM7:TR?= M3nF[HNCVkeHUh?=
BC-1 Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;mOmlEPTB;MkiuOlUyKM7:TR?= MkH3V2FPT0WU
NCI-H64 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4X1OWlEPTB;MkmuOlI2OyEQvF2= MWXTRW5ITVJ?
MOLT-16 M1rUSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\ZdWlEPTB;MkmuOlI6OiEQvF2= M4DicHNCVkeHUh?=
U-87-MG NHLyT5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzJ[pB1UUN3ME2zNE44PjZizszN M{P5SnNCVkeHUh?=
GAK MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TZT2lEPTB;M{GuNlY5PiEQvF2= MWfTRW5ITVJ?
ES8 M2KzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDJTWZKSzVyPUOyMlEzPTJizszN M2SxZnNCVkeHUh?=
HCC1599 M1zY[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTN{LkOzNlUh|ryP NU[5UWs5W0GQR1XS
EB-3 NGLRWJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGD1NHBKSzVyPUO0MlMyOTdizszN MUDTRW5ITVJ?
HCC1187 NFnHPYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPEWJpKSzVyPUO1MlgxPTJizszN MoO5V2FPT0WU
SK-PN-DW NWXBcmlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\tbZhKSzVyPUO2MlE6PDNizszN M1uzS3NCVkeHUh?=
JVM-3 M4DiRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HEe2lEPTB;M{euNlM{QCEQvF2= MYrTRW5ITVJ?
HCC2157 Mn;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLVOZFKSzVyPUO3Mlk6PDZizszN NILveXFUSU6JRWK=
A4-Fuk NHGzPIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTN6LkGwNFkh|ryP MUDTRW5ITVJ?
COR-L279 MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvLcpVXUUN3ME20NE4zQDVzIN88US=> NH\mR|VUSU6JRWK=
DEL MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPvTWM2OD12MT65NFg3KM7:TR?= Ml7TV2FPT0WU
NCI-H1395 M1LWRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXruSopLUUN3ME20Nk4xOTZ|IN88US=> MmXBV2FPT0WU
MHH-NB-11 NV;ad2xvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;GTWM2OD12Mz6wPFE5KM7:TR?= MnjXV2FPT0WU
NCI-H2107 M4LlWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MomwTWM2OD12Mz60PFQ3KM7:TR?= M1LHd3NCVkeHUh?=
NEC8 M3HBS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPSPYhKSzVyPUS0MlM{PiEQvF2= NWPYbm9MW0GQR1XS
COLO-684 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLSTWM2OD12Nj6yNlU5KM7:TR?= NXTPOFlOW0GQR1XS
LS-411N MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLrTWM2OD12OD60O|Q5KM7:TR?= M1;EU3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416); 

PubMed: 23049975     


Protein levels of phosphorylated c-Abl (Tyr245), c-Abl, phosphorylated c-Src (Tyr416), c-Src, and GAPDH in NSC-34 cells overexpressing human wild-type or mutant SOD1s treated with various concentrations of dasatinib were measured by western blot. Cells were cultured in serum-free culture medium with doxycycline (Dox, 2 µg/ml), and western blot was performed at 24 h after dasatinib addition.

p27 / p21; 

PubMed: 20145167     


Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for 48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for comparable protein loading.

p-FAK / p-STAT3; 

PubMed: 23721490     


The effect of dasatinib in cell signalling. Western blot analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC cell lines after 24 hours treatment of dasatinib. The cell lines were arranged according to their IC50 to dasatinib. The top three were most sensitive, the bottom 3 were least sensitive.

cleaved caspase 3; 

PubMed: 20145167     


Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves as loading control.

23049975 20145167 23721490
Growth inhibition assay
IC50; 

PubMed: 23721490     


9 HCC cell lines were exposed to the dedicated concentrations of dasatinib for 72 hours, and IC50 was tested by MTS. Results represent the mean (± SD) of three experiments.

23721490
Immunofluorescence
SRC / Met; 

PubMed: 26517812     


Immunocytochemistry of SRC and Met localization. Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively.

F-actin / Actinin-4 / Paxillin; 

PubMed: 31053734     


Conditionally immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei (Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars = 50 µm). Podocytes treated with dasatinib showed a marked decrease in cell-to-cell contacts, cell size and number of focal adhesions.

α-tubulin; 

PubMed: 26517812     


Combination of dasatinib and crizotinib impedes the formation of the α-tubulin-labeled mitotic spindle. LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.

26517812 31053734
ELISA
TNF-α; 

PubMed: 17684099     


U937 cells were differentiated with vitamin D3, pretreated with the indicated concentrations of drugs for 1 h and stimulated with LPS for 6 h. TNF-α secretion was measured by ELISA. The graph shows the mean of two experiments done in duplicate.

E-selectin; 

PubMed: 31110200     


HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of E-selectin was determined using ELISA (n = 3, ±SEM).

VCAM-1; 

PubMed: 31110200     


HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of VCAM-1 was determined using ELISA (n = 3, ±SEM).

17684099 31110200
In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

Protocol

Kinase Assay:

[1]

- Collapse

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research:

[1]

- Collapse
  • Cell lines: Ba/F3 cell lines
  • Concentrations: ~32 nM
  • Incubation Time: 72 hours
  • Method:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (Only for Reference)
Animal Research:

[3]

- Collapse
  • Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 488.01
Formula

C22H26ClN7O2S

CAS No. 302962-49-8
Storage powder
in solvent
Synonyms BMS-354825

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04063124 Not yet recruiting Drug: Dasatinib + Quercetin Alzheimer Disease The University of Texas Health Science Center at San Antonio|Mayo Clinic December 2019 Phase 1|Phase 2
NCT04115059 Not yet recruiting Drug: Dasatinib Waldenstrom Macroglobulinemia|DASATINIB Jorge J. Castillo MD|Bristol-Myers Squibb|Dana-Farber Cancer Institute November 2019 Phase 1
NCT03318770 Not yet recruiting Drug: Dasatinib and blinatumomab Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto December 2018 --
NCT03625388 Recruiting Drug: Dasatinib Chronic Myelogenous Leukemia Hikma Pharmaceuticals LLC November 5 2018 Phase 2
NCT03193281 Recruiting Drug: Dasatinib|Drug: Imatinib Chronic Myeloid Leukemia University of Auckland New Zealand|Leukaemia & Blood Cancer New Zealand July 17 2017 Phase 2
NCT03041701 Recruiting Drug: Dasatinib|Drug: Ganitumab Rhabdomyosarcoma|Rhabdomyosarcoma- Alveolar|Rhabdomyosarcoma-Embryonal National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7 2017 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • Answer:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • Question 2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • Answer:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Tags: buy Dasatinib | Dasatinib supplier | purchase Dasatinib | Dasatinib cost | Dasatinib manufacturer | order Dasatinib | Dasatinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID